ClinicalTrials.gg
RecruitingNCT04419649Updated Oct 19, 2026

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

A Phase 2 interventional study of Elritercept in Myelodysplastic Syndromes and Cytopenia, sponsored by Takeda. Recruiting at 53 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 2 months later.
Updated Oct 19, 2026Enrollment updatedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Myelodysplastic Syndromes by Takeda — 4 open to participants now, 4 under way, 2 of them phase 3. Myelodysplastic Syndromes · Takeda.

Planned enrollment
4th of 12
210 · median 66
Started
2020
the only one that year
Phase 2
4 of 13
2 open now
Registered
8th of 13
by date

Among the 13 studies in Myelodysplastic Syndromes by Takeda, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2020, is one of 4 in phase 2, and was the 8th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

4 of the 13 studies in Myelodysplastic Syndromes by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Myelodysplastic Syndromes by Takeda, or all of them as a file.
02

Study summary

The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the study and learn about the effects of elritercept on anemia linked to MDS. The study will also look to learn how elritercept affects the production of healthy RBCs.

Read the detailed description

Elritercept (KER-050) is a recombinant fusion protein being studied to increase red blood cell production by inhibiting the signaling of a subset of the transforming growth factor beta (TGF-ß) family of proteins.

03

Conditions studied

  • Myelodysplastic Syndromes
  • Cytopenia

Keywords

  • Transfusion
  • Drug Therapy
  • Elritercept
  • TAK-226
  • KER-050
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information in accordance with national and local study participant privacy regulations.
  2. Male or female ≥ 18 years of age, at the time of signing informed consent.
  3. (ECOG) performance status of 0, 1, or 2 (if related to anemia).
  4. Females of and sexually active males must agree to use highly effective methods of .
  5. In the opinion of the Investigator, the participant is able and willing to comply with the requirements of the protocol (e.g., all study procedures, return for follow-up visits).

Part 1 Inclusion Criteria

Participants are eligible to be included in Part 1 of the study only if all the following criteria apply:

  1. Diagnosis of MDS according to WHO classification that meets International Prognostic Scoring System-Revised (IPSS-R) classification of very low, low, or intermediate risk disease.
  2. Less than (\<)5 percent (%) blasts in bone marrow during the Pretreatment Period.
  3. Peripheral blood white blood cell (WBC) count \<13,000/microliter (μL) during the Pretreatment Period.
  4. Anemia defined as:

    1. In non-transfused participants, having received no RBC transfusions within 8 weeks, concentration ≤ 10.0 g/dL during the Pretreatment Period. OR
    2. In LTB participants, having received 1 to 3 units of RBCs for Hgb ≤ 9.0 g/dL within 8 weeks of the Pretreatment Period. OR
    3. In HTB participants, having received ≥ 4 units of RBCs for Hgb ≤ 9.0 g/dL within 8 weeks of the Pretreatment Period.

Part 1 Extension - Abbreviated Inclusion Criteria

Participants from Part 1 are eligible to be included in Part 1 Extension of the study only if all the following criteria apply:

  1. Previously completed 4 cycles of elritercept in Part 1 with no dose-limiting toxicities (DLTs).
  2. Participant has the potential to benefit from administration of elritercept, in the opinion of the Investigator.
  3. \< 5% blasts in bone marrow.
  4. Peripheral WBC count \< 13,000/μL during the 28 days prior to cycle 5 day 1 (C5D1).

Part 2 Inclusion Criteria

Participants are eligible to be included in Part 2 of the study only if all the following criteria apply:

  1. Cohort A:

    • Diagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • ring sideroblast (RS)-positive as defined by WHO 2016 criteria.
    • Requiring at least 2 units of RBC transfusions in the preceding 8 weeks before cycle 1 day 1 (C1D1).
  2. Cohort B:

    • Diagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • Non-RS as defined by WHO 2016 criteria.
    • Requiring at least 2 units of RBC transfusions in the 8 weeks before C1D1.
  3. Cohort C:

    • Diagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • Has anemia, defined by Hgb ≤ 10 g/dL during the Pretreatment Period, and received no RBC transfusion in the 8 weeks before C1D1.
  4. Cohort D:

    • Diagnosis of CMML according to WHO 2016 classification.
    • Has anemia, defined by Hgb ≤ 10 g/dL during the Pretreatment Period, and received no RBC transfusion in the 8 weeks before C1D1. OR
    • Received at least 2 units of RBC transfusions for anemia in the 8 weeks before C1D1.
  5. Cohort E:

    • Diagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • Requiring ≥ 2 units of RBC transfusions in the preceding 8 weeks before C1D1.
    • Receipt of ≥ 20 units of RBC in transfusion over the participant's lifetime.
    • Serum ferritin > 1000 nanograms per milliliter (ng/mL) on ≥ 2 assessments in the preceding 8 weeks before C1D1.
    • Treated with stable dose of iron chelation therapy for ≥ 8 weeks prior to C1D1.
  6. Cohort F:

    • Diagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • Requiring ≥ 2 units of RBC transfusions in the preceding 8 weeks before C1D1.
    • Receipt of ≥ 20 units of RBC in transfusion over the participant's lifetime.
    • Serum ferritin > 1000 ng/mL on ≥ 2 assessments in the preceding 8 weeks before C1D1.
    • Not treated with iron chelation therapy in the preceding 8 weeks before C1D1 and not eligible to initiate iron chelation therapy in the opinion of the Investigator and in accordance with local treatment guidelines for initiation of iron chelation therapy.
  7. Cohort G:

    • Diagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • RS-positive as defined by WHO 2016 criteria OR non-RS as defined by WHO 2016 criteria.
    • , refractory, or intolerant to luspatercept treatment

      • Relapsed is defined as documentation of response to luspatercept therapy followed by subsequent development of a need for transfusion(s), whether the transfusion need develops during luspatercept treatment or after luspatercept has been discontinued.
      • Refractory is defined as documentation of no response with luspatercept ≥ 1 mg/kg administered for ≥ 12 weeks duration.
      • Intolerant is defined as documentation of discontinuation of luspatercept therapy due to intolerance including, discontinuation because of any adverse event (serious or nonserious) at any time after treatment initiation.
    • Has anemia, defined as either of the following:

      • Has received at least 1 unit of RBC transfusions for anemia in the 8 weeks before C1D1; OR
      • Hgb ≤ 10 g/dL, and received no RBC transfusion in the 8 weeks before C1D1

        • Erythropoietin (EPO) \< 500 international units per liter (U/L) at Baseline.
    • Last dose of luspatercept is ≥ 3 weeks from C1D1.
  8. \< 5% blasts in bone marrow assessed by bone marrow aspirate during the Pretreatment Period.

Part 1 Exclusion Criteria

Participants are excluded from Part 1 of the study if any of the following criteria apply.

Medical History

  1. Diagnosis of MDS with deletion of chromosome 5q (Del5q).
  2. Active infection requiring parenteral antibiotic therapy within 28 days prior to C1D1 or oral antibiotics within 14 days of C1D1. Prophylactic antibiotics and/or antifungals for neutropenia are allowed.
  3. Presence of uncontrolled heart disease or (NYHA) Class III or IV heart failure.
  4. History of drug or alcohol abuse (as defined by the Investigator) within the past 2 years.
  5. History of stroke, deep venous thrombosis (DVT), or arterial embolism within 6 months prior to C1D1.
  6. Major surgery within 28 days prior to C1D1. Participants must be completely recovered from any previous surgery prior to C1D1.
  7. Known positive for (HIV), active infectious virus (HBV), or active infectious virus (HCV). Participants without known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.
  8. Any other than MDS that has not been in remission and/or has required systemic therapy including radiation, chemotherapy, hormonal therapy, or surgery, within 1 year prior to C1D1. Diagnosis of secondary MDS (i.e., MDS known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases).
  9. History of solid organ or hematological transplantation.
  10. Presence of uncontrolled hypertension, defined as systolic blood pressure (BP) ≥ 150 mmHg or diastolic BP ≥ 100 mmHg despite adequate treatment.
  11. (BMI) ≥ 40 kilograms per meter square (kg/m\^2) during the Pretreatment Period.
  12. History of severe allergic or anaphylactic reaction(s) or to recombinant proteins or in the medicinal product (IMP).

Treatment History

  1. Prior treatment with azacitidine, decitabine, lenalidomide, luspatercept, or sotatercept.
  2. Treatment with ESA within 56 days prior to C1D1.
  3. Prior or concurrent chronic treatment with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF).
  4. Iron chelation therapy if initiated within 8 weeks prior to C1D1.
  5. Vitamin B12 therapy initiated within 8 weeks prior to C1D1. Participants on stable replacement doses for ≥ 8 weeks and without concurrent vitamin B12 or folate deficiency are allowed.
  6. Treatment with another investigational drug or device or approved therapy for investigational use ≤ 28 days prior to C1D1, or, if the half-life of the previous product is known, within 5 times the half-life prior to C1D1, whichever is longer.

Laboratory Exclusions (during Pretreatment Period)

  1. count > 450 ✕ 10\^9/L or \< 30 ✕ 10\^9/L.
  2. Transferrin saturation \< 15%.
  3. Ferritin \< 50 nanograms per milliliter (ng/mL).
  4. Folate \< 4.5 nanomoles per liter (nmol/L) (\< 2.0 ng/mL).
  5. Vitamin B12 \< 148 picomoles per liter (pmol/L) (\< 200 picograms per milliliter [pg/mL]).
  6. Estimated (GFR) \< 30 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2), as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
  7. Positive for HIV.

Miscellaneous

  1. Pregnant or lactating females.
  2. Any other condition not specifically noted above which, in the opinion of the Investigator, would preclude the participant from participating in the study.
  3. Participants who are investigational site staff members directly involved in the conduct of the trial and their immediate family members, site staff members otherwise supervised by the Investigator, or participants who are Sponsor or contract research organization (CRO) employees directly involved in the conduct of the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

Part 1 Extension - Exclusion Criteria

Participants from Part 1 are excluded from Part 1 Extension of the study if any of the following criteria apply.

Medical History

  1. Discontinuation of IMP in Part 1 for any reason.
  2. Has not completed a study visit in the past 12 months.
  3. Active infection requiring parenteral antibiotic therapy within 28 days prior to C5D1 or oral antibiotics within 14 days of C5D1. Prophylactic antibiotics and/or antifungals for neutropenia are allowed.
  4. Presence of uncontrolled heart disease or NYHA Class III or IV heart failure.
  5. History of drug or alcohol abuse (as defined by the Investigator) within the past 2 years.
  6. History of stroke, DVT, or arterial embolism within 6 months prior to C5D1.
  7. Major surgery within 28 days prior to C5D1. Participants must be completely recovered from any previous surgery prior to C5D1.
  8. Known positive for HIV, active infectious HBV, or active infectious HCV. Participants without known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.
  9. Any malignancy other than MDS that has not been in remission and/or has required systemic therapy including radiation, chemotherapy, hormonal therapy, or surgery, within 1 year prior to C5D1.
  10. History of solid organ or hematological transplantation.
  11. Presence of uncontrolled hypertension, defined as systolic BP ≥ 150 mmHg or diastolic BP ≥ 100 mmHg despite adequate treatment.
  12. BMI ≥ 40 kg/m\^2 during the 28 days prior to C5D1.

Treatment History

  1. Prior treatment with azacitidine, decitabine, lenalidomide, luspatercept, or sotatercept.
  2. Treatment with ESA within 56 days prior to C5D1.
  3. Prior or concurrent chronic treatment with G-CSF or GM-CSF.
  4. Iron chelation therapy if initiated within 8 weeks prior to C5D1.
  5. Vitamin B12 with treatment initiated within 8 weeks prior to C5D1. Participants on stable replacement doses for ≥ 8 weeks and without concurrent vitamin B12 or folate deficiency are allowed.
  6. Treatment with another investigational drug or device or approved therapy for investigational use ≤ 28 days prior to C5D1, or, if the half-life of the previous product is known, within 5 times the half-life prior to C5D1, whichever is longer. Previous treatment with elritercept is acceptable.

Laboratory Exclusions (during Abbreviated Pretreatment Period)

  1. Platelet count > 450 × 10\^9/L or \< 30 × 10\^9/L.
  2. Transferrin saturation \< 15%.
  3. Ferritin \< 50 ng/mL.
  4. Folate \< 4.5 nmol/L (\< 2.0 ng/mL).
  5. Vitamin B12 \< 148 pmol/L (\< 200 pg/mL).
  6. Estimated GFR \< 30 mL/min/1.73 m\^2, as determined by the CKD-EPI equation.

Miscellaneous

  1. Pregnant or lactating females.
  2. Any other condition not specifically noted above which, in the opinion of the Investigator, would preclude the participant from participating in the study.
  3. Participants who are investigational site staff members directly involved in the conduct of the trial and their immediate family members, site staff members otherwise supervised by the Investigator, or participants who are Sponsor or CRO employees directly involved in the conduct of the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

Part 2 Exclusion Criteria

Participants are excluded from Part 2 of the study if any of the following criteria apply.

Medical History

  1. Diagnosis of MDS with Del5q.
  2. Diagnosis of secondary MDS (i.e., MDS known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases).
  3. Active infection requiring parenteral antibiotic therapy within 28 days prior to C1D1 or oral antibiotics within 14 days of C1D1. Prophylactic antibiotics and/or antifungals for neutropenia are allowed.
  4. Presence of the following cardiac conditions:

    1. Presence of uncontrolled heart disease or NYHA Class III or IV heart failure.
    2. (QT interval corrected by Fridericia's formula) > 500 msec on the screening or C1D1 (ECG; mean of 3 measurements).
    3. Uncontrolled arrhythmia (participants with rate-controlled atrial fibrillation are not excluded).
    4. Acute myocardial infarction or unstable angina pectoris ≤ 6 months prior to C1D1.
  5. Presence of uncontrolled hypertension, defined as systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite adequate treatment.
  6. History of stroke, DVT, or arterial embolism within 6 months prior to C1D1.
  7. History of drug or alcohol abuse (as defined by the Investigator) within the past 2 years.
  8. Major surgery within 28 days prior to C1D1. Participants must be completely recovered from any previous surgery prior to C1D1.
  9. Any malignancy other than MDS or CMML that has not been in remission and/or has required major surgery or systemic therapy including radiation, chemotherapy, targeted therapy, or hormonal therapy within 1 year prior to C1D1.
  10. History of solid organ or hematological transplantation.
  11. Diagnosis of hemolytic anemia, active bleeding, hemoglobinopathies, or congenital disorders as a cause of the participant's anemia.
  12. Grade ≥ 2 bleeding events within the 3 months prior to C1D1.
  13. Receipt of an RBC or platelet transfusion for any reason(s) or combination of reasons other than underlying MDS within the 16 weeks prior to C1D1. If a participant requires a transfusion for an unanticipated reason during the Pretreatment Period, a prolonged screening period may be considered after discussion with the Medical Monitor.
  14. Known positive for HIV, active infectious HBV with positive viral load (HBV DNA), or active infectious HCV with positive viral load (HCV RNA). Participants without known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.
  15. BMI ≥ 40 kg/m\^2.
  16. History of severe allergic or anaphylactic reaction(s) or hypersensitivity to recombinant proteins or excipients in the IMP.
  17. Diagnosis of cirrhosis, non-alcoholic steatohepatitis, alcoholic liver disease, hepatitis, or other liver disease (acute or chronic) meeting C criteria for hepatic impairment. Participants with elevated liver enzymes are allowed if the liver enzyme elevation is suspected to be due to iron-overload or iron chelation, and other hepatic causes have been ruled out, in the opinion of the Investigator.

Treatment History

  1. Prior treatment with azacitidine, decitabine, lenalidomide, or sotatercept.
  2. Prior treatment with luspatercept (Cohorts A, B, C, D, E, and F only).
  3. Treatment with ESA within 8 weeks prior to C1D1.
  4. Iron chelation therapy if initiated within 8 weeks prior to C1D1. Participants on stable doses of iron chelation therapy for ≥ 8 weeks are allowed.
  5. Vitamin B12 and/or folate therapy initiated within 8 weeks prior to C1D1. Participants on stable replacement doses for ≥ 8 weeks and without concurrent vitamin B12 or folate deficiency are allowed.
  6. Any need to receive a prohibited medication.
  7. Treatment with another investigational drug or device or approved therapy for investigational use within 8 weeks prior to C1D1, or, if the half-life of the previous product is known, within 5 times the half-life prior to C1D1, whichever is longer.

Laboratory Exclusions (during Pretreatment Period)

  1. Platelet count > 800 × 10\^9/L or \< 25 × 10\^9/L.
  2. Ferritin \< 50 ng/mL.
  3. Folate \< 4.5 nmol/L (\< 2.0 ng/mL).
  4. Vitamin B12 \< 148 pmol/L (\< 200 pg/mL).
  5. Estimated GFR \< 30 mL/min/1.73 m\^2 as determined by the CKD-EPI equation.

Miscellaneous

  1. Pregnant or lactating females.
  2. Any other condition not specifically noted above which, in the opinion of the Investigator, would preclude the participant from participating in the study.
  3. Participants who are investigational site staff members directly involved in the conduct of the trial and their immediate family members, site staff members otherwise supervised by the Investigator, or participants who are Sponsor or CRO employees directly involved in the conduct of the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

For Cohort G ONLY:

  1. Any luspatercept related AE Grade ≥ 3 that has not resolved to baseline or Grade ≤ 1.
  2. History of allergy/anaphylaxis/hypersensitivity to luspatercept.
  3. Prior treatment with imetelstat.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Part 1: Elritercept Cohort 1

    Participants will be administered elritercept at 0.75 milligrams per kilogram (mg/kg), subcutaneous (SC) injection, every 4 weeks on Day 1 of each cycle for up to 4 cycles (each cycle = 28 days). Following the above dose regimen, participants will continue to receive elritercept, administered SC, on Day 1, every 4 weeks up to 24 cycles (each cycle = 28 days).

    Drug: Elritercept

  • Experimental
    Part 1: Elritercept Cohort 2

    Participants will be administered elritercept at 1.5 mg/kg, SC injection, every 4 weeks on Day 1 of each cycle for up to 4 cycles (each cycle = 28 days). Following the above dose regimen, participants will continue to receive elritercept, administered SC, on Day 1, every 4 weeks up to 24 cycles (each cycle = 28 days).

    Drug: Elritercept

  • Experimental
    Part 1: Elritercept Cohort 3

    Participants will be administered elritercept at 2.5 mg/kg, SC injection, every 4 weeks on Day 1 of each cycle for up to 4 cycles (each cycle = 28 days). Following the above dose regimen, participants will continue to receive elritercept, administered SC, on Day 1, every 4 weeks up to 24 cycles (each cycle = 28 days).

    Drug: Elritercept

  • Experimental
    Part 1: Elritercept Cohort 4

    Participants will be administered elritercept at 3.75 mg/kg, SC injection, every 4 weeks on Day 1 of each cycle for up to 4 cycles (each cycle = 28 days). Following the above dose regimen, participants will continue to receive elritercept, administered SC, on Day 1, every 4 weeks up to 24 cycles (each cycle = 28 days).

    Drug: Elritercept

  • Experimental
    Part 1: Elritercept Cohort 5

    Participants will be administered elritercept at 5.0 mg/kg, SC injection, every 4 weeks on Day 1 of each cycle for up to 4 cycles (each cycle = 28 days). Following the above dose regimen, participants will continue to receive elritercept, administered SC, on Day 1, every 4 weeks up to 24 cycles(each cycle = 28 days).

    Drug: Elritercept

  • Experimental
    Part 2: Elritercept Dose Confirmation Cohort A

    Participants with ring sideroblasts (RS)-positive Myelodysplastic syndrome (MDS) who are requiring red blood cell (RBC) transfusions will be administered Elritercept at 3.75 mg/kg, SC injection, on Day 1, every 4 weeks for up to 24 cycles (each cycle = 28 days). The dose can be modified based on participant's response.

    Drug: Elritercept

  • Experimental
    Part 2: Elritercept Dose Confirmation Cohort B

    Participants with non-RS MDS who are requiring RBC transfusions will be administered Elritercept at 3.75 mg/kg, SC injection, on Day 1, every 4 weeks for up to 24 cycles (each cycle = 28 days). The dose can be modified based on participant's response.

    Drug: Elritercept

  • Experimental
    Part 2: Elritercept Dose Confirmation Cohort C

    Participants who are non-transfused with either RS-positive MDS or non-RS MDS will be administered Elritercept at 3.75 mg/kg, SC injection, on Day 1, every 4 weeks for up to 24 cycles (each cycle = 28 days). The dose can be modified based on participant's response.

    Drug: Elritercept

  • Experimental
    Experimental: Part 2: Elritercept Dose Confirmation Cohort D

    Participants with chronic myelomonocytic leukemia (CMML) and anemia will be administered Elritercept at 3.75 mg/kg, SC injection, on Day 1, every 4 weeks for up to 24 cycles (each cycle = 28 days). The dose can be modified based on participant's response.

    Drug: Elritercept

  • Experimental
    Part 2: Elritercept Dose Confirmation Cohort E

    Participants with MDS (either RS-positive or non-RS) who are requiring RBC transfusions, have iron-overload, and are receiving iron chelation therapy will be administered Elritercept at 3.75 mg/kg, SC injection, on Day 1, every 4 weeks for up to 24 cycles (each cycle = 28 days). The dose can be modified based on participant's response.

    Drug: Elritercept

  • Experimental
    Part 2: Elritercept Dose Confirmation Cohort F

    Participants with MDS (either RS-positive or non-RS) who are requiring RBC transfusions, have iron-overload, and are not receiving iron chelation therapy will be administered Elritercept at 3.75 mg/kg, SC injection, on Day 1, every 4 weeks for up to 24 cycles (each cycle = 28 days). The dose can be modified based on participant's response.

    Drug: Elritercept

  • Experimental
    Part 2: Elritercept Dose Confirmation Cohort G

    Participants with MDS (either RS-positive or non-RS) who have relapsed after treatment with luspatercept, become refractory to luspatercept treatment, or are intolerant to luspatercept treatment will be administered Elritercept at 3.75 mg/kg, SC injection, on Day 1, every 4 weeks for up to 24 cycles (each cycle = 28 days). The dose can be modified based on participant's response.

    Drug: Elritercept

  • Experimental
    Long-term Extension Cohort

    Participants from Part 1 and 2 cohorts who may have potential benefit from continued elritercept treatment, in the opinion of the Investigator, may elect to continue in the LTE at the same dose they were being administered in Part 1 and 2, SC injection, on day 1, every 4 weeks until end of treatment (EOT) (approximately 122 months).

    Drug: Elritercept

Interventions

  • Elritercept SC injection.

    Also known as: KER-050, TAK-226

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An AE is defined as any untoward medical occurrence, in a clinical study participant administered a medicinal product, that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not it is related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that, at any dose: results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

    Time frame: From treatment initiation to end of study (up to 11.2 years)

Secondary outcomes

  1. Number of Participants with Progression to Higher Risk MDS or Acute Myeloid Leukemia (AML)

    The progression to higher risk MDS or AML will be assessed as per the World Health Organization (WHO) 2016 criteria.

    Time frame: From study day 1 through end of study (up to 11.2 years)

  2. Percentage of Participants with Low Transfusion Burden (LTB) and High Transfusion Burden (HTB) who Achieve RBC Transfusion Independence (TI)

    Participants with LTB and HTB achieving RBC TI greater than or equal to (≥) 8 weeks, overall RBC TI and based on RS status will be assessed.

    Time frame: From study day 1 through end of study (up to 11.2 years)

  3. Percentage of Participants who Achieve Hematologic Improvement Erythroid (HI-E) Response Based on Modified 2006 International Working Group (IWG)

    The response is defined as a mean hemoglobin (Hgb) increase of ≥1.5 grams per deciliter (g/dL) from Baseline during any 8-week period during the treatment period for LTB participants and participants with non-transfused anemia, and is defined as a reduction by ≥ 4 units of RBCs transfused during any 8-week period on study compared with the 8-week period prior to study cycle 1 day 1 (C1D1) (cycle length = 28 days) for HTB participants. Participants achieving overall HI-E response and based on RS status will be assessed.

    Time frame: From study day 1 to end of study (up to 11.2 years)

  4. Percentage of Participants who Achieve Overall Erythroid Response

    The response is defined as a mean hemoglobin (Hgb) increase of ≥1.5 grams per deciliter (g/dL) from Baseline during any 8-week period during the treatment period for LTB participants and participants with non-transfused anemia, and is defined as a reduction by ≥ 4 units of RBCs transfused during any 8-week period on study compared with the 8-week period prior to study cycle 1 day 1 (C1D1) (cycle length = 28 days) for HTB participants. TI is defined as RBC transfusion independence for ≥ 8 weeks. Overall erythroid response is defined as HI-E or TI over any 8-week period. Participants achieving overall erythroid response and based on RS status will be assessed.

    Time frame: Up to approximately 11.2 years

  5. Percentage of Participants who Achieve Erythropoietic Improvement

    The improvement is defined as a mean Hgb increase of ≥1.5 g/dL from Baseline for ≥14 days (in the absence of RBC transfusions) for LTB participants and participants with non-transfused anemia and is defined as a reduction of ≥50% or ≥4 RBC units transfused compared with pretreatment over an 8-week period for HTB participants. Participants achieving overall improvement and based on RS status will be assessed.

    Time frame: Up to approximately 11.2 years

  6. Mean Change from Baseline in Hgb

    At each visit, the mean of the change from baseline in Hgb will be calculated across participants.

    Time frame: Baseline, multiple timepoints post treatment up to 11.2 years

  7. Time to HI-E Response

    The response is defined as a mean hemoglobin (Hgb) increase of ≥1.5 grams per deciliter (g/dL) from Baseline during any 8-week period during the treatment period for LTB participants and participants with non-transfused anemia, and is defined as a reduction by ≥ 4 units of RBCs transfused during any 8-week period on study compared with the 8-week period prior to study cycle 1 day 1 (C1D1) (cycle length = 28 days) for HTB participants.

    Time frame: Up to approximately 11.2 years

  8. Duration of HI-E Response

    The response is defined as a mean hemoglobin (Hgb) increase of ≥1.5 grams per deciliter (g/dL) from Baseline during any 8-week period during the treatment period for LTB participants and participants with non-transfused anemia, and is defined as a reduction by ≥ 4 units of RBCs transfused during any 8-week period on study compared with the 8-week period prior to study cycle 1 day 1 (C1D1) (cycle length = 28 days) for HTB participants.

    Time frame: Up to approximately 11.2 years

  9. Time to TI Response

    TI is defined as RBC transfusion independence for ≥ 8 weeks.

    Time frame: Up to approximately 11.2 years

  10. Duration of TI response

    TI is defined as RBC transfusion independence for ≥ 8 weeks.

    Time frame: Up to approximately 11.2 years

  11. Percentage of LTB and HTB Participants who Achieve TI

    Time frame: Weeks 12, 16, 24 and 48

  12. Number of Participants with Change from Baseline in Red Cell Parameters

    The red cell parameters including reticulocyte count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and reticulocyte cell Hgb will be assessed.

    Time frame: Up to approximately 11.2 years

07

Study locations

35 of 53 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Oct 2029, 110 months after the start.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 110 months is above that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2020
First posted
Jun 5, 2020
StartActual
Aug 19, 2020
Primary completionEst.
Oct 30, 2029
CompletionEst.
Oct 30, 2031
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
160→210
Oct 19, 2026
Eligibility
18 criteria edited, 3 added, 7 removed
What changed in the criteria
  • EditedLess than (<)5percent5 percent (%) blasts in bone marrow during the Pretreatment Period.
  • EditedIn non-transfused participants, having received no RBC transfusions within 8 weeks, Hgb concentration ≤ 10.0 g/dL during the Pretreatment Period. OR
  • EditedIn LTB participants, having received 1 to 3 units of RBCs for Hgb ≤ 9.0 g/dL within 8 weeks of the Pretreatment Period. OR
  • RemovedOR
  • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
  • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
  • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
  • EditedDiagnosis of CMML according to WHO 2016 classification.
  • EditedHas anemia, defined by Hgb ≤ 10 g/dL during the Pretreatment Period, and received no RBC transfusion in the 8 weeks before C1D1. OR
  • RemovedOR
  • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
  • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
  • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
  • ChangedBefore Relapsed, refractory, or intolerant to frontline luspatercept treatment and have not received an interceding therapy (for example, erythropoiesis-stimulating agent [ESA])Now Relapsed, refractory, or intolerant to luspatercept treatment
  • EditedRelapsed is defined as documentation of response to luspatercept therapy andfollowed by subsequent development of a need for transfusion(s), whether the transfusion need develops during luspatercept treatment or after luspatercept has been discontinued.
  • EditedIntolerant is defined as documentation of discontinuation of luspatercept therapy due to intolerance including, discontinuation because of any adverse event (serious or an AEnonserious) at any time after introductiontreatment initiation.
  • RemovedRequiring ≥ 2 units of RBC transfusions over 8 weeks prior to C1D1.
  • AddedHas anemia, defined as either of the following:
  • AddedHas received at least 1 unit of RBC transfusions for anemia in the 8 weeks before C1D1; OR
  • AddedHgb ≤ 10 g/dL, and received no RBC transfusion in the 8 weeks before C1D1
  • EditedLast dose of luspatercept is ≥ 3 weeks and < 12 months from C1D1.
  • RemovedPrior or concurrent chronic treatment with G-CSF or GM-CSF, for reasons other than for treatment of MDS.
  • RemovedNote: Previous treatment with G-CSF or GM-CSF for MDS, which has been discontinued ≥ 8 weeks prior to C1D1 is allowed.
  • RemovedPeripheral WBC count ≥ 13,000/μL.
  • EditedPlatelet count > 450800 × 10\^9/L or < 25 × 10\^9/L.
  • RemovedTransferrin saturation < 15%.
  • EditedNo historyHistory of allergy/anaphylaxis/hypersensitivity to luspatercept.
  • EditedNo priorPrior treatment with imetelstat.
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Enrollment 160→210
    Eligibility 18 criteria edited, 3 added, 7 removed
    What changed in the criteria
    • EditedLess than (<)5percent5 percent (%) blasts in bone marrow during the Pretreatment Period.
    • EditedIn non-transfused participants, having received no RBC transfusions within 8 weeks, Hgb concentration ≤ 10.0 g/dL during the Pretreatment Period. OR
    • EditedIn LTB participants, having received 1 to 3 units of RBCs for Hgb ≤ 9.0 g/dL within 8 weeks of the Pretreatment Period. OR
    • RemovedOR
    • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • EditedDiagnosis of CMML according to WHO 2016 classification.
    • EditedHas anemia, defined by Hgb ≤ 10 g/dL during the Pretreatment Period, and received no RBC transfusion in the 8 weeks before C1D1. OR
    • RemovedOR
    • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • EditedDiagnosis of MDS according to WHO 2016 classification that meets IPSS-R classification of very low, low, or intermediate risk disease.
    • ChangedBefore Relapsed, refractory, or intolerant to frontline luspatercept treatment and have not received an interceding therapy (for example, erythropoiesis-stimulating agent [ESA])Now Relapsed, refractory, or intolerant to luspatercept treatment
    • EditedRelapsed is defined as documentation of response to luspatercept therapy andfollowed by subsequent development of a need for transfusion(s), whether the transfusion need develops during luspatercept treatment or after luspatercept has been discontinued.
    • EditedIntolerant is defined as documentation of discontinuation of luspatercept therapy due to intolerance including, discontinuation because of any adverse event (serious or an AEnonserious) at any time after introductiontreatment initiation.
    • RemovedRequiring ≥ 2 units of RBC transfusions over 8 weeks prior to C1D1.
    • AddedHas anemia, defined as either of the following:
    • AddedHas received at least 1 unit of RBC transfusions for anemia in the 8 weeks before C1D1; OR
    • AddedHgb ≤ 10 g/dL, and received no RBC transfusion in the 8 weeks before C1D1
    • EditedLast dose of luspatercept is ≥ 3 weeks and < 12 months from C1D1.
    • RemovedPrior or concurrent chronic treatment with G-CSF or GM-CSF, for reasons other than for treatment of MDS.
    • RemovedNote: Previous treatment with G-CSF or GM-CSF for MDS, which has been discontinued ≥ 8 weeks prior to C1D1 is allowed.
    • RemovedPeripheral WBC count ≥ 13,000/μL.
    • EditedPlatelet count > 450800 × 10\^9/L or < 25 × 10\^9/L.
    • RemovedTransferrin saturation < 15%.
    • EditedNo historyHistory of allergy/anaphylaxis/hypersensitivity to luspatercept.
    • EditedNo priorPrior treatment with imetelstat.
    + 4 other changes: verification date, arm descriptions, data sharing statement and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04419649
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 5, 2020
Start date
Aug 19, 2020
Primary completion
Oct 30, 2029 (estimated)
Completion
Oct 30, 2031 (estimated)
Last update
Oct 19, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elritercept

Start the discussion